January 19, 2022

Kate Onyejekwe, experte en santé publique, dirigera le bureau de Washington de JSI

WASHINGTON, 19 janvier 2022 /PRNewswire/ — John Snow, Inc. (JSI), est fier d’annoncer que Kate Onyejekwe a été nommée au poste de directrice du bureau de la Division internationale à Washington, DC.

Mme Onyejekwe assurera la direction et la supervision de la programmation du portefeuille de 75 projets dans 40 pays, de sept centres de compétences techniques et des équipes de services aux entreprises du bureau de Washington, DC.

« Ma passion a toujours été de servir les gens et les collectivités partout dans le monde pour créer des systèmes de santé solides, renforcer la résilience et faciliter des services de santé équitables pour tous. Ce rôle offre une plate-forme encore plus grande à la Division internationale et à JSI dans son ensemble pour continuer à façonner et à faire progresser le programme mondial de santé publique », a déclaré Mme Onyejekwe.

Plus récemment, Mme Onyejekwe était directrice adjointe du programme MOMENTUM Integrated Health Resilience, où elle supervisait le personnel mondial et les partenariats régionaux et nationaux pour atteindre les objectifs de programmation au niveau national.

Mme Onyejekwe possède plus de 25 ans d’expérience technique et en gestion de programmes dans les domaines de la planification familiale et de la santé génésique, de la santé maternelle et infantile, de l’immunisation, des programmes relatifs au VIH, au genre et à la jeunesse, de la santé communautaire, du renforcement des capacités, de la gestion pharmaceutique et de la gestion financière et opérationnelle dans des contextes multiculturels. Son travail dans plus de 14 pays souligne son engagement à innover et à galvaniser les nations, les communautés, les familles et les individus afin qu’ils perfectionnent leurs compétences et créent des solutions durables à leurs problèmes de santé et de développement prioritaires, en particulier pendant l’ère de la COVID-19.

John Snow, Inc. , et le JSI Research & Training Institute sont des organismes de consultation en gestion de la santé publique et de recherche voués à l’amélioration de la santé des personnes et des communautés partout dans le monde. Nous travaillons en partenariat avec des organismes communautaires, le secteur privé et des agences gouvernementales afin de renforcer leur capacité de rationaliser les services, de former leur personnel, de recueillir et d’utiliser des données, de promouvoir des comportements sains, et consolider les chaînes d’approvisionnement afin de fournir de meilleurs services de santé à tous.

Contact :
Pamela Bond, Conseillère principale en communication
pamela_bond@JSI.com

Photo – https://mma.prnewswire.com/media/1729021/Kate_Onyejekwe.jpg

Logo – https://mma.prnewswire.com/media/400895/JSI_Logo.jpg

January 19, 2022

Public Health Expert Kate Onyejekwe to Lead JSI’s Washington Office

WASHINGTON, Jan. 19, 2022 /PRNewswire/ — John Snow, Inc. (JSI), is proud to announce that Kate Onyejekwe has been appointed to the position of International Division Washington, DC, office director.

Onyejekwe will provide leadership and programmatic oversight to the Washington, DC-based portfolio of 75 projects in 40 countries, seven technical core competency centers, and the office’s corporate services teams.

“My passion has always been to serve people and communities around the world to engender strong health systems, build resilience, and facilitate equitable health services for all. This role provides an even greater platform for the International Division, and JSI as a whole, to continue to shape and advance the global public health agenda,” said Onyejekwe.

Most recently, Onyejekwe was deputy director of the MOMENTUM Integrated Health Resilience program, where she oversaw global staff and regional and country-level partnerships to achieve country-level programming goals.

John Snow, Inc. Logo Onyejekwe has more than 25 years of technical and program management experience in family planning and reproductive health; maternal and child health; immunization; HIV gender and youth programming; community health; capacity building; pharmaceutical management; and financial and operational management in multicultural settings. Her work in more than 14 countries underpins her commitment to innovate with and galvanize nations, communities, families, and individuals to advance their skills and create lasting solutions to their priority health and development challenges, especially during the COVID-19 era.

John Snow, Inc, and the nonprofit JSI Research & Training Institute are public health management consulting and research organizations dedicated to improving the health of individuals and communities throughout the world. We partner with community-based organizations, the private sector, and government agencies to strengthen their capacity to streamline services, develop their workforce, collect and use data, promote healthy behaviors, and strengthen supply chains in an effort to deliver better health services to all.

Contact:
Pamela Bond, Senior Communications Advisor
pamela_bond@JSI.com

Photo – https://mma.prnewswire.com/media/1729021/Kate_Onyejekwe.jpg
Logo – https://mma.prnewswire.com/media/400895/JSI_Logo.jpg

January 19, 2022

Seegene to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing

Scheduled to launch in late January, Seegene’s new COVID-19 test supports swift, large-scale lab testing with the same degree of accuracy as the conventional PCR test

SEOUL, South Korea, Jan. 19, 2022 /PRNewswire/ — Seegene Inc. (KQ 096530), South Korea’s leading molecular diagnostics company, announced today the upcoming launch of the Allplex™ SARS-CoV-2 Fast PCR Assay, which can deliver PCR results in just 60 minutes. The company says that this assay is expected to reduce the total turnaround time to a third and expand testing capacity up to 3 times for hospitals and laboratories without additional instruments or compromise on accuracy.

Reduction of the turnaround time was attributable to two primary reasons: 1) the application of a novel enzyme developed by Seegene, which reduces PCR process time to half. 2) Seegene’s innovative extraction-free method, which can let Allplex™ SARS-CoV-2 Fast PCR Assay be available without the extraction of the sample preparation in PCR-based tests. This drastically reduces the total turnaround time for each result. As such, the new assay lessens the amount of hands-on processing time required, allowing facilities to triple their testing capacity in the same hour.

“This assay will be the optimized choice for laboratories and hospitals where they conduct large-scale testing as it helps them immediately expand the testing capacity with lessening the burden of healthcare workers,” said Ho Yi, Chief Sales and Marketing Officer of Seegene. “For the time being, we plan to target large-scale testing markets in more than 60 countries all across the globe. The next step in our journey is to develop a new gold-standard molecular diagnostic assay that fully matches the speed of antigen tests with the same degree of accuracy as PCR test”

The Allplex™ SARS-CoV-2 Fast PCR Assay targets three COVID-19 genes––E, RdRP, and N–– to reliably detect COVID-19 regardless of the variants. According to clinical research conducted by 17 laboratories in seven countries, this assay showed the same or better accuracy for the COVID-19 detection as other diagnostic tests available in the market.

Visit www.seegene.com for more information.

About Seegene, Inc.

Seegene, Inc. was founded in Seoul, South Korea in 2000 and has subsidiaries in the U.S.A., Canada, Germany, Italy, Mexico, Brazil, Colombia, and the Middle East. Seegene, Inc. is an in-vitro diagnostics (IVD) company that has been turning innovative technologies into products through its pioneering R&D activities. Seegene owns its original patent technology including DPO™ (Dual Priming Oligonucleotide) for multiple target amplification; TOCE™ for multiple target detection in a single channel; MuDT™, the world’s first real-time PCR technology that provides individual Ct values for multiple targets in a single channel for quantitative assays.; and mTOCE™ multiplex mutation detection technology. With these cutting-edge molecular diagnostic (MDx) technologies applied to diagnostic kits and other tools, Seegene has enhanced the sensitivity, specificity, and disease-coverage per a test of PCR (polymerase chain reaction) to unprecedented levels by providing accurate high-multiplex PCR products that target and detect genes of multiple pathogens simultaneously per each fluorescence channel. This feature dramatically saves testing time and cost. Seegene continues to set new standards in MDx through cutting-edge innovations.

Photo – https://mma.prnewswire.com/media/1728443/N.jpg

Logo – https://mma.prnewswire.com/media/1357790/Seegene_logo_Logo.jpg

January 19, 2022

OKX toma o segundo posto das bolsas de criptomoedas, reposiciona sua marca como prestadora de serviços de plataforma cruzada

A nova marca OKX, anteriormente OKEx, destaca o robusto conjunto de produtos de investimento em criptografia, NFT e DeFi da plataforma

VICTORIA, Seychelles, Jan. 18, 2022 (GLOBE NEWSWIRE) — A OKX, que recentemente se tornou a segunda maior bolsa de criptomoedas do mundo em volume de negociação à vista, divulgou hoje a nova marca da empresa que reflete o dinamismo e a adoção acelerada da criptomoeda. Fundada em 2017 como um serviço de negociação de criptomoedas, a OKX acumulou mais de 20 milhões de usuários e expandiu seu conjunto de produtos de investimentos em ativos digitais para incluir a OKX Earn, uma ferramenta para renda com receita passiva de criptomoedas; um marketplace de NFT e um hub descentralizado de descoberta de aplicativos; e mais recentemente, a MetaX, o novo modo descentralizado da OKX que contém um painel de cadeia cruzada e uma carteira Web 3.0 de auto custódia para armazenamento de ativos digitais, incluindo NFTs.

Essa mudança, demonstrada pela mudança do nome da empresa de OKEx para OKX, reflete o número crescente de oportunidades de criação de riqueza da plataforma além da bolsa, que os investidores usam para negociar centenas de ativos digitais nos mercados spot, de margem e de derivativos.

Como parte da mudança, a OKX disse que sua missão é “remover as barreiras de criação de patrimônios, viabilizando o acesso a tudo o que nosso futuro descentralizado possa oferecer”. Isso ressalta a evolução contínua da plataforma em direção à descentralização, que inclui dar aos investidores a opção de auto custódia de seus ativos digitais. Ao contrário de outras bolsas centralizadas de criptomoedas, a OKX está comprometida em diminuir gradualmente o nível de envolvimento da empresa nas atividades do usuário, com o objetivo final de eliminar completamente a intermediação.

“A OKX está indo além do modelo das bolsas centralizadas padrão, oferecendo para os nossos clientes uma experiência completa de criptomoeda”, disse Jay Hao, CEO da OKX. “E o mais importante, estamos fazendo isso enquanto defendemos os princípios fundamentais da criptografia — descentralização e autonomia. Nosso objetivo é fornecer aos clientes as ferramentas necessárias para que eles possam ganhar, transferir e gastar seu patrimônio de forma fácil e segura, conforme julgarem adequado, sem a nossa intermediação. Nós tiramos o ‘E’ do nosso nome porque somos muito mais do que uma bolsa, assim como a criptografia é muito mais do que um ativo especulativo.”

A OKX, com mais de 250 ativos digitais e há muito ocupando o primeiro lugar em volumes de negociação de futuros de criptomoedas, recentemente se tornou a segunda maior plataforma de negociação spot de criptomoedas do mundo. Em 2021, o volume total de negociações na plataforma, incluindo instrumentos spot e derivativos, aumentou mais de 700%, enquanto o número de negociações executadas na plataforma aumentou mais de 480%. As ofertas de staking, poupança e DeFi via OKX Earn tiveram mais de US$ 5,1 bilhões depositados pelos usuários e pagaram mais de US$ 314 milhões em renda passiva no ano passado.

Para mais informação, visite OKX.com e siga @OKX no Twitter.

Sobre a OKX

Fundada em 2017, a OKX é uma bolsa de criptomoedas e um ecossistema líder mundial. A OKX adotou de forma inovadora a tecnologia blockchain para reformular o ecossistema financeiro e oferece alguns dos produtos, soluções e ferramentas de negociação mais diversificados e sofisticados do mercado. Mais de 20 milhões de pessoas em 180 regiões em todo o mundo confiam na OKX que tem como missão remover as barreiras à criação de patrimônios, oferecendo acesso a tudo o que o futuro descentralizado possa oferecer. Com seu compromisso inabalável com a inovação, a OKX visualiza um mundo de inclusão financeira para todos através do poder das criptomoedas e das finanças descentralizadas.

Contato

Email: media@okx.com
Olivia Capozzalo:
olivia.capozzalo@okx.com
@oliviacap (Telegram)

January 19, 2022

OKX dépasse les échanges de cryptomonnaies mondiales en tant que deuxième plus grand fournisseur de services multi-plateformes

Anciennement OKEx, la nouvelle marque d’OKX met en avant la suite robuste de produits d’investissement crypto, NFT et DeFi de la plateforme

VICTORIA, Seychelles, 18 janv. 2022 (GLOBE NEWSWIRE) — OKX, qui est récemment devenue la deuxième plus grande bourse de cryptomonnaies au monde en termes de volume de transactions au comptant, a annoncé aujourd’hui un changement de marque à l’échelle de l’entreprise qui reflète le dynamisme et l’accélération de l’adoption de la cryptomonnaie. Fondée en 2017 en tant que service de trading de cryptomonnaies, OKX a depuis rassemblé plus de 20 millions d’utilisateurs et étendu sa suite de produits d’investissement dans des actifs numériques pour inclure OKX Earn, un outil permettant de gagner des revenus passifs en cryptomonnaies ; une place de marché NFT et une plateforme décentralisée de découverte d’applications ; et plus récemment, MetaX, le nouveau mode décentralisé d’OKX qui comprend un tableau de bord inter-chaînes et un portefeuille Web 3.0 en garde personnelle pour stocker les actifs numériques, y compris les NFT.

Cette évolution, comme le souligne le changement de nom de la société d’OKEx à OKX, reflète le nombre croissant d’opportunités de création de richesses de la plateforme au-delà de la bourse, que les investisseurs utilisent pour négocier des centaines d’actifs numériques sur les marchés au comptant, de marges et de dérivés.

Dans le cadre de cette initiative, OKX a déclaré que sa mission consistait à « supprimer les obstacles à la création de richesses en vous donnant accès à tout ce que notre avenir décentralisé nous réserve ». Cela souligne l’évolution continue de la plateforme vers la décentralisation, qui inclut l’option de donner aux investisseurs la possibilité de conserver eux-mêmes leurs actifs numériques. Se distinguant des autres bourses de cryptomonnaies centralisées, OKX s’engage à réduire progressivement le niveau d’implication de la société dans l’activité des utilisateurs, dans le but ultime de supprimer entièrement l’intermédiation.

« OKX va au-delà du modèle d’échange centralisé standard pour offrir à nos clients une expérience de cryptomonnaie de bout en bout », a commenté Jay Hao, PDG d’OKX. « Plus important encore, nous le faisons tout en respectant les principes fondamentaux des cryptomonnaies : la décentralisation et l’autonomie. Notre objectif est de donner aux clients les outils dont ils ont besoin pour gagner, transférer et dépenser facilement et en toute sécurité la richesse qu’ils jugent appropriée, sans intermédiation de notre part. Nous avons abandonné le “E” de notre nom parce que nous sommes bien plus qu’une bourse, tout comme la cryptomonnaie est bien plus qu’un actif spéculatif. »

OKX, qui répertorie plus de 250 actifs numériques et occupe depuis longtemps la première place pour les volumes de trading à terme de cryptomonnaies, est récemment devenue la deuxième plus grande plateforme de trading au comptant de cryptomonnaies au monde. En 2021, le volume de trading total sur la plateforme, y compris les instruments au comptant et dérivés, a augmenté de plus de 700 %, tandis que le nombre de négociations exécutées sur la plateforme a augmenté de 480 %. Les offres de staking, d’épargne et de DeFi via OKX Earn ont enregistré plus de 5,1 milliards de dollars déposés par les utilisateurs, et ont versé plus de 314 millions de dollars de revenus passifs au cours de l’année écoulée.

Pour en savoir plus, veuillez consulter OKX.com et suivez la société @OKX sur Twitter.

À propos d’OKX

Fondée en 2017, OKX est un écosystème et une bourse de cryptomonnaies de premier plan au niveau mondial. OKX a adopté de manière innovante la technologie blockchain pour remodeler l’écosystème financier et propose certains des produits, solutions et outils de négociation les plus variés et les plus sophistiqués du marché. Avec la confiance de plus de 20 millions de personnes dans 180 régions à travers le monde, la mission d’OKX consiste à supprimer les obstacles à la création de richesses en offrant un accès à tout ce que l’avenir décentralisé réserve. Avec son engagement inébranlable en faveur de l’innovation, OKX envisage un monde d’inclusion financière pour tous grâce à la puissance des cryptomonnaies et de la finance décentralisée.

Contactez-nous

E-mail : media@okx.com
Olivia Capozzalo :
olivia.capozzalo@okx.com
@oliviacap (Telegram)

January 19, 2022

US Billionaire Opens COVID, Cancer Vaccine Plant in South Africa

South African-born U.S. billionaire Patrick Soon-Shiong and South African President Cyril Ramaphosa have cut the ribbon Wednesday at a new vaccine manufacturing plant. It is hoped the facility will soon start making Africa’s first locally produced COVID-19 vaccines, as well as cancer vaccines and other pharmaceuticals.

A crowd of ceremony participants cheered as Dr. Soon-Shiong and President Ramaphosa took the stage at the NantSA vaccine manufacturing campus at a business park in Cape Town.

Soon-Shiong, 69, left South Africa after doing his internship to become a medical doctor. Today, he is number 89 on the Forbes 400 list of wealthiest Americans with an estimated fortune of $7.5 billion. A transplant surgeon by profession, he became known for inventing the cancer treatment drug Abraxane.

He says the COVID-19 vaccine he has developed is second generation and will stop the transmission of the virus. However, he emphasized the vaccines currently available are effective and necessary.

“It is so important for you to be vaccinated. These vaccines that were there played a very important role as I would say, not a stopgap measure because it’s first generation, but it did absolutely reduce death and it does continue to do so. So, I want to make sure that people understand that you need to be vaccinated,” Soon-Shiong said.

However, he said today’s vaccines aren’t the final answer to the pandemic.

“Unfortunately, two things happen: the antibodies wane and the viruses mutate and you get yourself into a spiral, which then opens up the opportunity for the second-generation vaccine. So, the first-generation vaccine was absolutely not a waste of time. However, we needed to, in parallel, I believe, focus on the second-generation vaccine so that we stop the transmission,” Soon-Shiong said.

Ramaphosa, who has been campaigning for vaccine manufacturers to give up their patent rights so that all countries can produce COVID-19 vaccines, said discussions with the World Trade Organization on this continue.

“The demand that we have been making, initiated by both India and South Africa is that we want the world, or those who have the capacity to manufacture the drug substance to transfer their technology so that we are able to manufacture ourselves the drug substance. And this is where the real challenge has been. We want to migrate from just doing fill and finish and be able to manufacture the drug substance ourselves,” Ramaphosa said.

The president and Soon-Shiong also launched the Coalition to Accelerate Africa’s Access to Advanced Healthcare, known as the AAAH Coalition. It aims to hasten domestic production of pharmaceuticals and vaccines that will reach patients across the African continent.

The Africa Regional Director for the World Health Organization, Matshidiso Moeti, congratulated Ramaphosa and Soon-Shiong on the launch, saying it was a proud day for Africa.

“This new vaccine manufacturing campus will be an important space contributing to the eco system for manufacturing capacity. It will contribute positively to Africa’s response to COVID-19, as well as cancer, HIV, childhood preventable diseases, neglected tropical diseases and other diseases,” Moeti said.

Soon-Shiong said it will cost about 196 million dollars to complete the plant. He says once it is fully operational, his company hopes to produce about 1 billion COVID-19 vaccine doses by 2025.

Source: Voice of America